KX01 (Tirbanibulin)
Gastric/Gastro-esophageal/Esophageal Cancers
Key Facts
Indication
Gastric/Gastro-esophageal/Esophageal Cancers
Phase
Phase I
Status
Status Unclear (per 2017 history)
Company
About PharmaEssentia
PharmaEssentia's mission is to build a global leader in hematologic oncology by unlocking the therapeutic potential of interferons through innovative molecular engineering. Its key achievement is the successful global commercialization of BESREMi®, the first FDA-approved interferon for polycythemia vera (PV), marking a significant milestone for Taiwan's biotech sector. The company's strategy leverages a fully integrated model—from R&D and manufacturing to global commercialization—to expand its lead in MPNs and explore new indications. Following its 2024 IPO, PharmaEssentia is positioned to scale its operations and advance a promising pipeline.
View full company profile